Description
VatalanibisaninhibitorofVEGFRthatiscurrentlyinclinicaltrialsforthetreatmentofmyelodysplasticsyndrome,lymphomas,non-smallcelllungcancers(NSCLCs),andothercancers.Vatalanibexhibitsanti-angiogenic,anti-metastatic,anticancerchemotherapeutic,andanalgesicactivities.Inanimalmodelswithmammarycarcinomaallografts,vatalanibdecreasestumorvascularization.Inanimalmodelsofpancreaticcarcinoma,vatalanibinhibitstumorgrowthandmetastasisanddecreasesmicrovesseldensity.Additionally,vatalanibdecreaseschronicneuropathicpaininanimalmodelsofchronicconstrictioninjury,asinhibitionofVEGFR2inhibitssignalingthroughneuropathicpain-mediatingP2X(2/3)receptors.
References
GuptaP,MulkeyF,HasserjianRP,etal.AphaseIIstudyoftheoralVEGFreceptortyrosinekinaseinhibitorvatalanib(PTK787/ZK222584)inmyelodysplasticsyndrome:CancerandLeukemiaGroupBstudy10105(Alliance).InvestNewDrugs.2013Oct;31(5):1311-20.PMID:23700288.
LiuS,XuC,LiG,etal.VatalanibdecreasethepositiveinteractionofVEGFreceptor-2andP2X2/3receptorinchronicconstrictioninjuryrats.NeuRochemInt.2012May;60(6):565-72.PMID:22361062.
GaulerTC,BesseB,MauguenA,etal.PhaseIItrialofPTK787/ZK222584(vatalanib)admiNISTeredorallyonce-dailyorintwodivideddailydosesassecond-linemonotherapyinrelapsedorprogressingpatientswithstageIIIB/IVnon-small-celllungcancer(NSCLC).AnnOncol.2012Mar;23(3):678-87.PMID:21617019.
HlushchukR,RiestererO,BaumO,etal.TumorrecoverybyangiogenicswitchfromsproutingtointussusceptiveangiogenesisaftertreatmentwithPTK787/ZK222584orionizingrADIation.AmJPathol.2008Oct;173(4):1173-85.PMID:18787105.
SolorzanoCC,BakerCH,BrunsCJ,etal.InhibitionofgrowthandmetastasisofhumanpancreaticcancergrowinginnudemicebyPTK787/ZK222584,aninhibitorofthevascularendothelialgrowthfactorreceptortyrosinekinases.CancerBiotherRadiopharm.2001Oct;16(5):359-70.PMID:11776753.
